Article
Oncology
Stefanie Hiltbrunner, Zoe Fleischmann, Ethan S. Sokol, Martin Zoche, Emanuela Felley-Bosco, Alessandra Curioni-Fontecedro
Summary: This study analyzed the molecular characteristics of a large cohort of pleural and peritoneal mesothelioma samples, identifying some alterations with potential therapeutic targets and suggesting that molecular profiling can lead to new treatment options for patients with mesothelioma.
BRITISH JOURNAL OF CANCER
(2022)
Review
Medicine, General & Internal
Sam M. Janes, Doraid Alrifai, Dean A. Fennell
Summary: Mesothelioma, mostly caused by asbestos exposure, has a decreasing incidence but high mortality due to late diagnosis and treatment resistance. Pemetrexed-cisplatin and immune checkpoint inhibitors have shown modest survival extension.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Ben Johnson, Ling Zhuang, Emma M. Rath, Man Lee Yuen, Ngan Ching Cheng, Huaikai Shi, Steven Kao, Glen Reid, Yuen Yee Cheng
Summary: Malignant pleural mesothelioma (MPM) is a deadly thoracic malignancy with limited treatment options. Chemotherapy is the most common treatment, but drug resistance is a challenge. MicroRNA transfection can enhance MPM cell sensitivity to chemotherapy drugs, and influence the response to survivin (YM155) small molecule inhibitor treatment.
Review
Oncology
Dean A. Fennell, Sean Dulloo, James Harber
Summary: ICIs have greatly improved the treatment of mesothelioma, but the predictive biological features of response to ICIs are still poorly understood. Rational combinations involving ICIs are being studied and there is emerging evidence of synergistic antitumour activity. Non-ICI-based immunotherapies also show promising efficacy. Results from trials of dendritic cell vaccines and viral cytokine delivery, among others, are eagerly awaited.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Iose Di Stefano, Greta Ali, Anello Marcello Poma, Rossella Bruno, Agnese Proietti, Cristina Niccoli, Carmelina Cristina Zirafa, Franca Melfi, Maria Giovanna Mastromarino, Marco Lucchi, Gabriella Fontanini
Summary: Pleural mesothelioma (PM) consists of three main subtypes: epithelioid, biphasic and sarcomatoid, with different impacts on prognosis and treatment. This study used immunohistochemistry to evaluate the expression of five markers in PM subtypes. Mesothelin and Claudin-15 were found to have good sensitivity and specificity for the epithelioid subtype, while Complement Factor B and p21-activated Kinase 4 had inferior performance. In biphasic PM, all markers showed different expression in the different components.
Article
Cell Biology
Surein Arulananda, Megan O'Brien, Marco Evangelista, Laura J. Jenkins, Ashleigh R. Poh, Marzena Walkiewicz, Trishe Leong, John M. Mariadason, Jonathan Cebon, Srividya B. Balachander, Justin R. Cidado, Erinna F. Lee, Thomas John, Walter D. Fairlie
Summary: The study found that the inhibitor AZD4320 targeting BCL-XL can effectively kill malignant pleural mesothelioma tumor cells, with enhanced effects when used in combination with AZD5991. A novel nanoparticle, AZD0466, showed similar effectiveness to standard chemotherapy drug Cisplatin in inhibiting tumor growth in mouse xenograft studies, while reducing thrombocytopenia associated with BCL-XL inhibition.
CELL DEATH DISCOVERY
(2021)
Article
Pharmacology & Pharmacy
Wanyuan Cui, Sanjay Popat
Summary: Immune checkpoint inhibitors have shown important but variable efficacy in mesothelioma treatment, with combination ICI therapy appearing more promising. A randomized Phase 3 trial has established ipilimumab-nivolumab as a new standard of care, but there are still unresolved issues such as predictive biomarkers and patient selection.
Article
Oncology
Ildiko Kovacs, Edina Bugyik, Katalin Dezso, Julia Tarnoki-Zach, Elod Mehes, Marton Gulyas, Andras Czirok, Elisabeth Lang, Michael Grusch, Karin Schelch, Balazs Hegedus, Ildiko Horvath, Nandor Barany, Zsolt Megyesfalvi, Anna Tisza, Zoltan Lohinai, Mir Alireza Hoda, Konrad Hoetzenecker, Francesco Pezzella, Sandor Paku, Viktoria Laszlo, Balazs Dome
Summary: This study investigates the microanatomical steps of malignant pleural mesothelioma (MPM) vascularization and the resistance mechanisms to anti-angiogenic drugs in MPM. The study reveals two distinct growth patterns of orthotopically implanted human MPM xenografts, invasive pattern and pushing/desmoplastic pattern.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Masayuki Watanabe, Tomohito Higashi, Kana Ozeki, Atsuko Y. Higashi, Kotaro Sugimoto, Hayato Mine, Hironori Takagi, Yuki Ozaki, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki, Hideki Chiba
Summary: This study identified claudin-15 as a potential positive marker for malignant pleural mesotheliomas, with high expression levels in 83% of MPM tissue samples. The specificity of CLDN15 was comparable to other markers in lung adenocarcinoma sections. CLDN15 showed low expression in non-mesothelial tumors, suggesting its potential clinical utility for MPM diagnosis.
SCIENTIFIC REPORTS
(2021)
Article
Biotechnology & Applied Microbiology
Valeria Panzetta, Ida Musella, Sabato Fusco, Paolo A. Netti
Summary: Malignant pleural mesothelioma is a rare but devastating tumor that is difficult to diagnose and treat effectively. Effusion cytology, although used for diagnosis, is time-consuming and has limited sensitivity. Therefore, alternative research methods are needed to support early diagnosis. Mechanobiology offers new perspectives and diagnostic tools for the mechanical and biophysical characterization of malignant pleural mesothelioma cells.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Oncology
Anne S. Tsao, Harvey Pass, Andreas Rimner, Aaron S. Mansfield
Summary: Malignant pleural mesothelioma (MPM) is a rare malignancy with limited treatment options. Recent advances have led to changes in treatment standards, including the use of a novel biomedical device in combination with platinum-pemetrexed and the inclusion of immunotherapy as a frontline treatment option. Proper identification of the MPM histology is crucial in determining the optimal treatment plan. Immunotherapy can benefit all MPM patients and should be considered at some point during treatment. Ongoing research is focusing on defining frontline therapy in the unresectable setting and addressing immunotherapy refractory cases.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Erica C. Nakajima, Paz J. Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Youwei Bi, Hisham Qosa, Jiang Liu, Hong Zhao, Missiratch Biable, Lauren Tesh Hotaki, Yuan-Li Shen, Richard Pazdur, Julia A. Beaver, Harpreet Singh, Martha Donoghue
Summary: Nivolumab with ipilimumab has been approved by the FDA as first-line treatment for unresectable MPM. The combination therapy showed improved overall survival compared to chemotherapy. The approval was obtained through FDA's Orbis project and international collaboration.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Antonia Marazioti, Anthi C. Krontira, Sabine J. Behrend, Georgia A. Giotopoulou, Giannoula Ntaliarda, Christophe Blanquart, Hasan Bayram, Marianthi Iliopoulou, Malamati Vreka, Lilith Trassl, Mario A. A. Pepe, Caroline M. Hackl, Laura Klotz, Stefanie A. Weiss, Ina Koch, Michael Lindner, Rudolph A. Hatz, Juergen Behr, Darcy E. Wagner, Helen Papadaki, Sophia G. Antimisiaris, Didier Jean, Sophie Deshayes, Marc Gregoire, Ozgecan Kayalar, Deniz Mortazavi, Sukru Dilege, Serhan Tanju, Suat Erus, Omer Yavuz, Pinar Bulutay, Pinar Firat, Ioannis Psallidas, Magda Spella, Ioanna Giopanou, Ioannis Lilis, Anne-Sophie Lamort, Georgios T. Stathopoulos
Summary: A portion of human MPM cases have mutations in KRAS, and mouse models suggest that KRAS mutations can lead to MPM, especially when combined with TP53 deletion. These findings indicate that KRAS alterations may play an important and underestimated role in certain MPM patients.
EMBO MOLECULAR MEDICINE
(2022)
Article
Oncology
Moshe Lapidot, Abigail E. Case, Ellen L. Weisberg, Chengcheng Meng, Sarah R. Walker, Swati Garg, Wei Ni, Klaus Podar, Yin P. Hung, Ruben D. Carrasco, Aine Knott, Prafulla C. Gokhale, Sunil Sharma, Alex Pozhitkov, Prakash Kulkarni, David A. Frank, Ravi Salgia, James D. Griffin, Srinivas V. Saladi, Raphael Bueno, Martin Sattler
Summary: The study revealed that KDM4A is overexpressed in MPM patients and inhibiting its enzymatic activity efficiently reduces cell growth and tumor volume. KDM4A expression is associated with pathways involved in cell growth and DNA repair.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Elisabet Aliagas, Ania Alay, Maria Martinez-Iniesta, Miguel Hernandez-Madrigal, David Cordero, Mireia Gausachs, Eva Pros, Maria Saigi, Sara Busacca, Annabel J. Sharkley, Alan Dawson, Ramon Palmero, Jose C. Ruffinelli, Susana Padrones, Samantha Aso, Ignacio Escobar, Ricard Ramos, Roger Llatjos, August Vidal, Eduard Dorca, Mar Varela, Montse Sanchez-Cespedes, Dean Fennell, Cristina Munoz-Pinedo, Alberto Villanueva, Xavi Sole, Ernest Nadal
Summary: The study demonstrates that CDK4/6 inhibitors can reduce proliferation of MPM cells by promoting G1 cell cycle arrest and inducing cell senescence. This suggests the potential of using CDK4/6 inhibitors for the treatment of MPM in clinical settings.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Raffit Hassan, Anish Thomas, John J. Nemunaitis, Manish R. Patel, Jaafar Bennouna, Franklin L. Chen, Jean-Pierre Delord, Afshin Dowlati, Samith T. Kochuparambil, Matthew H. Taylor, John D. Powderly, Ulka N. Vaishampayan, Claire Verschraegen, Hans Juergen Grote, Anja von Heydebreck, Kevin Chin, James L. Gulley
Editorial Material
Oncology
Vincent Vinh-Hung, Nam P. Nguyen, Claire Verschraegen
Article
Oncology
Yi-Zhou Jiang, Ding Ma, Chen Suo, Jinxiu Shi, Mengzhu Xue, Xin Hu, Yi Xiao, Ke-Da Yu, Yi-Rong Liu, Ying Yu, Yuanting Zheng, Xiangnan Li, Chenhui Zhang, Pengchen Hu, Jing Zhang, Qi Hua, Jiyang Zhang, Wanwan Hou, Luyao Ren, Ding Bao, Bingying Li, Jingcheng Yang, Ling Yao, Wen-Jia Zuo, Shen Zhao, Yue Gong, Yi-Xing Ren, Ya-Xin Zhao, Yun-Song Yang, Zhenmin Niu, Zhi-Gang Cao, Daniel G. Stover, Claire Verschraegen, Virginia Kaklamani, Anneleen Daemen, John R. Benson, Kazuaki Takabe, Fan Bai, Da-Qiang Li, Peng Wang, Leming Shi, Wei Huang, Zhi-Ming Shao
Meeting Abstract
Oncology
Daniel Spakowicz, Mingjia Li, Rebecca Hoyd, Jarred Thomas Burkart, Sandip H. Patel, Marium Husain, Kai He, Carolyn J. Presley, Erin Marie Bertino, Peter G. Shields, David Paul Carbone, Hiral A. Shah, Gabriel Tinoco, Edmund Folefac, Priyanka Bhateja, Claire F. Verschraegen, Gregory Alan Otterson, Lang Li, Kari Lynn Kendra, Dwight Hall Owen
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
Heather Wright, Cuke Melissa, Edmund Folefac, Claire F. Verschraegen, Marie Wood
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
Bhavana Konda, Sherise C. Rogers, Cassandra Natalie Grenade, Claire F. Verschraegen, Ye Zhou, Ashima Goyal, Mona Natwa, Chadwick Wright, Akram Hussein, Hallie Barr, Dramane Konate, Andrew Brown, Rochelle Batdorf, Bonnie Williams, Songzhu Zhao, Lai Wei, Manisha H. Shah
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
Vincent Vinh-Hung, Kadiatou Diakite, Clarisse Joachim, Stefanos Bougas, Cristina Ioana Furtos, Jean-Marc Rakotonarivo, Wadah Lababidi, Eva Papadopoulou, Patrick Escarmant, Jacqueline Veronique-Baudin, Claire F. Verschraegen
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Oncology
Mingjia Li, Daniel Spakowicz, Jarred Burkart, Sandip Patel, Marium Husain, Kai He, Erin M. Bertino, Peter G. Shields, David P. Carbone, Claire F. Verschraegen, Carolyn J. Presley, Gregory A. Otterson, Kari Kendra, Dwight H. Owen
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
V. Vinh-Hung, H. M. Dehbi, S. Bougas, D. Verellen, N. Leduc, C. Verschraegen, M. De Ridder, N. P. Nguyen
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Article
Oncology
Ming Yin, Jing Zhao, Paul Monk, Douglas Martin, Edmund Folefac, Monika Joshi, Ning Jin, Amir Mortazavi, Claire Verschraegen, Steven Clinton
Article
Medicine, General & Internal
Vincent Vinh-Hung, Nicolas Leduc, Jacqueline Baudin, Guy Storme, Nam P. Nguyen, Clarisse Joachim, Elsa Cecilia-Joseph, Claire Verschraegen
CUREUS JOURNAL OF MEDICAL SCIENCE
(2019)
Meeting Abstract
Oncology
Daniel Spakowicz, Marium Husain, Gabriel Tinoco, Sandip H. Patel, Jarred Thomas Burkart, Claire F. Verschraegen, Kari Lynn Kendra, Sarah Hoffman, Jennifer Philippon, Dionisia Marie Quiroga, Gregory Alan Otterson, Dwight Hall Owen
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Letter
Medicine, General & Internal
Ming Yin, Vincent Vinh-Hung, Claire Verschraegen
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Meeting Abstract
Oncology
Brooke Benner, Megan Duggan, Andrew Stiff, Bhavana Konda, Robert D. Rupert, Paul Monk, Claire Verschraegen, Hiral Shah, Anne Noonan, William E. Carson, Robert Wesolowski
Meeting Abstract
Oncology
Sant P. Chawla, Brian Andrew Van Tine, Seth Pollack, Kristen N. Ganjoo, Anthony D. Elias, Richard F. Riedel, Steven Attia, Edwin Choy, Scott H. Okuno, Mark Agulnik, Margaret von Mehren, Michael B. Livingston, Vicki Leigh Keedy, Claire F. Verschraegen, Tony Philip, Gerry C. Bohac, Sergey Yurasov, Hailing Lu, Michael Chen, Robert G. Maki
JOURNAL OF CLINICAL ONCOLOGY
(2019)